Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 15, 2026

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

View original at finance.yahoo.com

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026 Late-breaker presentations will highlight investigational, once-weekly oral combinations of islatravir with lenacapavir (Phase 3 ISL/LEN) and with ulonivirine (Phase 2b ISL+ULO) in adults with v…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Building on the momentum of the recent FDA approval of IDVYNSO, AIDS 2026 is an exciting moment to showcase the next chapter of Merck's HIV pipeline, particularly its focus on the potential of once-weekly oral treatments in combination with islatravir; the breadth of new data spanning daily, weekly and monthly investigational regimens demonstrates how Merck's research is continuing to evolve with the needs of the HIV community.
60% confidence